BR112017013253A2 - comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes - Google Patents
comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantesInfo
- Publication number
- BR112017013253A2 BR112017013253A2 BR112017013253A BR112017013253A BR112017013253A2 BR 112017013253 A2 BR112017013253 A2 BR 112017013253A2 BR 112017013253 A BR112017013253 A BR 112017013253A BR 112017013253 A BR112017013253 A BR 112017013253A BR 112017013253 A2 BR112017013253 A2 BR 112017013253A2
- Authority
- BR
- Brazil
- Prior art keywords
- oral disintegrating
- disintegrating tablet
- producing
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a comprimidos de desintegração oral (odt) de tofacitinibe e de seus sais farmaceuticamente aceitáveis e ao processo para produzir o odt. a invenção refere-se ainda a odts compreendendo tofacitinibe e seus sais farmaceuticamente aceitáveis, pelo menos um agente edulcorante, pelo menos um desintegrante e opcionalmente outros excipientes. o peso dos comprimidos de desintegração oral é de 200 mg ou menos. a invenção refere-se ainda a comprimidos de desintegração oral de citrato de tofacitinibe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2842MU2015 | 2015-07-27 | ||
| PCT/IB2016/053768 WO2017017542A1 (en) | 2015-07-27 | 2016-06-24 | Tofacitinib orally disintegrating tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017013253A2 true BR112017013253A2 (pt) | 2018-02-27 |
Family
ID=57885375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017013253A BR112017013253A2 (pt) | 2015-07-27 | 2016-06-24 | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10034882B2 (pt) |
| EP (1) | EP3328360A4 (pt) |
| JP (1) | JP6507272B2 (pt) |
| KR (1) | KR101964546B1 (pt) |
| BR (1) | BR112017013253A2 (pt) |
| PH (1) | PH12017502249A1 (pt) |
| WO (1) | WO2017017542A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3904356A4 (en) * | 2018-12-24 | 2022-09-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND |
| WO2021155254A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
| US11766438B2 (en) | 2020-04-24 | 2023-09-26 | Slayback Pharma Llc | Pharmaceutical compositions of tofacitinib for oral administration |
| IL297776A (en) | 2020-04-30 | 2022-12-01 | Nanocopoeia Llc | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib |
| WO2023086066A1 (en) * | 2021-11-15 | 2023-05-19 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising micronized tofacitinib |
| CN115381788B (zh) * | 2022-09-19 | 2023-07-11 | 苏州弘森药业股份有限公司 | 一种枸橼酸托法替布制剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GT200200234A (es) * | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| BRPI0808889A2 (pt) * | 2007-03-13 | 2014-11-11 | Dainippon Sumitomo Pharma Co | Comprimido desintegrante oral |
| ES2393640T3 (es) * | 2008-02-13 | 2012-12-26 | Dainippon Sumitomo Pharma Co., Ltd. | Comprimidos bucodisgregables |
| ES2400774T3 (es) * | 2008-06-13 | 2013-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Tableta que se disgrega rápidamente en la cavidad oral y método para producción de la misma |
| EP2377522B1 (en) | 2010-04-15 | 2013-01-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same |
| CA2895534C (en) * | 2012-12-20 | 2019-10-22 | Kashiv Pharma, Llc | Orally disintegrating tablet formulation for enhanced bioavailability |
| JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| WO2015051738A1 (en) * | 2013-10-08 | 2015-04-16 | Sunshine Lake Pharma Co., Ltd. | Tofacitinib citrate |
-
2016
- 2016-06-24 EP EP16829918.8A patent/EP3328360A4/en not_active Withdrawn
- 2016-06-24 BR BR112017013253A patent/BR112017013253A2/pt not_active IP Right Cessation
- 2016-06-24 US US15/521,496 patent/US10034882B2/en not_active Expired - Fee Related
- 2016-06-24 WO PCT/IB2016/053768 patent/WO2017017542A1/en active Application Filing
- 2016-06-24 JP JP2017565982A patent/JP6507272B2/ja not_active Expired - Fee Related
- 2016-06-24 KR KR1020177036631A patent/KR101964546B1/ko active IP Right Grant
-
2017
- 2017-12-11 PH PH12017502249A patent/PH12017502249A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101964546B1 (ko) | 2019-04-01 |
| KR20180030785A (ko) | 2018-03-26 |
| EP3328360A1 (en) | 2018-06-06 |
| EP3328360A4 (en) | 2019-01-02 |
| WO2017017542A1 (en) | 2017-02-02 |
| PH12017502249A1 (en) | 2018-05-28 |
| US20170304307A1 (en) | 2017-10-26 |
| JP6507272B2 (ja) | 2019-04-24 |
| US10034882B2 (en) | 2018-07-31 |
| JP2018521040A (ja) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017013253A2 (pt) | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
| MX2024010140A (es) | Nuevos metodos. | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| MY183526A (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| MX2021002322A (es) | Nuevos metodos. | |
| PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| TR201717703A2 (tr) | Api̇ksaban formülasyonlari | |
| EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
| SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| PE20151282A1 (es) | Combinacion de medicamentos que comprenden fenilefrina y paracetamol | |
| TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
| WO2019016673A3 (en) | STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB | |
| TR201821115A2 (tr) | Montelukast ve levoseti̇ri̇zi̇n i̇çeren farmasöti̇k bi̇leşi̇m | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| WO2019151966A3 (en) | Pharmaceutical tablet compositions of dabigatran |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |